Skip to content
BOLUS
Subscribe

Signal from the log

Star Therapeutics

200 M$ · United States · Biotech

Star Therapeutics, à South San Francisco, développe des traitements pour des maladies où les patients manquent de solutions ; son équipe a déjà inventé quatre traitements premiers de leur classe, aujourd'hui en phase 3 ou commercialisés. La levée, menée par OrbiMed et Janus Henderson Investors, suit la vente de sa filiale Vega Therapeutics en juillet.

Verified

Announced on , logged by the watch of 23 October 2026.

Operation
Funding round
Announced amount
200 M$
Country
United States
Sector
Biotech

What the log says

Editorial note, in French

Communiqué ouvert, montant relu et fonds nommés.

The investors

Led by OrbiMed , Janus Henderson Investors , with Agent Capital , Catalio Capital Management , Cormorant Asset Management , New Leaf Venture Partners , NYBC Ventures , RA Capital Management , Redmile , Sofinnova Investments , Soleus Capital

Provenance
Source biopharmadive,businesswire,divenewsletter,endpoints
Logged on 23 October 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.

One address, nothing else.

One letter a week, on Fridays: the week's funding rounds, the funds named, the amounts double checked. The list is never sold, one click to unsubscribe. The letter is written in French.

You are, if you care to say

Email confirmation before any subscription. The list is never sold. What Bolus knows about you is written on the privacy page (in French).